New cancer drug candidate BG-68501 enters first human trials
NCT ID NCT06257264
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrinks tumors, alone or with other drugs. About 103 adults with cancers like breast, ovarian, or lung cancer will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BG-68501 (a CDK2 inhibitor drug)
- What this could lead to
- If successful, this could lead to a new treatment option for advanced solid tumors like breast, ovarian, and lung cancers.
- What could go wrong
- This is a very early Phase 1 trial with only 103 participants, so safety and effectiveness are not yet proven. Many early-stage drugs fail to show benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Auckland City Hospital
Auckland, 1023, New Zealand
-
Avera Cancer Institute
Sioux Falls, South Dakota, 57105-2108, United States
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, NSW 2148, Australia
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
-
Cancer Research South Australia
Adelaide, South Australia, SA 5000, Australia
-
Florida Cancer Specialists and Research Institute
Lake Mary, Florida, 32746-2115, United States
-
Genesiscare North Shore
St Leonards, New South Wales, NSW 2065, Australia
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150000, China
-
Hoag Memorial Presbyterian
Newport Beach, California, 92663-4162, United States
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
Monash Health
Clayton, Victoria, VIC 3168, Australia
-
Nepean Hospital
Kingswood, New South Wales, NSW 2747, Australia
-
Princess Alexandra Hospital
Woolloongabba, Queensland, QLD 4102, Australia
-
Rambam Health Care Center
Haifa, 3109601, Israel
-
Saint Vincents Hospital Sydney
Darlinghurst, New South Wales, NSW 2010, Australia
-
Shaare Zedek Medical Center
Jerusalem, 9103102, Israel
-
Shengjing Hospital of China Medical Universityhuaxiang Branch
Shenyang, Liaoning, 110022, China
-
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)
Guangzhou, Guangdong, 510245, China
-
The First Affiliated Hospital of Xian Jiaotong University
Xi'an, Shaanxi, 710061, China
-
The Institute of Oncology, Arensia Exploratory Medicine
Chisinau, 2025, Moldova
-
Titan Health Partners Llc Dba Astera Cancer Care
East Brunswick, New Jersey, 08816-4096, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110-1010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a new tracer light up hidden prostate cancer?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Can your own immune cells beat advanced cancer?